Please login to the form below

Not currently logged in
Email:
Password:

Alexion Pharma

This page shows the latest Alexion Pharma news and features for those working in and with pharma, biotech and healthcare.

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

Alexion and NICE agree confidential discount for Ultomiris use on the NHS

stable after receiving Alexion’s older PNH drug Soliris (eculizumab) for six months or more. ... Compared with Alexion’s older drug, Ultomiris is a cost-effective use of NHS resources, concluded NICE.

Latest news

  • AstraZeneca to acquire Alexion for $39bn AstraZeneca to acquire Alexion for $39bn

    The deal means AZ will immediately gain assets within Alexion’s commercial portfolio, estimated to be worth around $6bn. ... Rare disease is increasingly becoming an area of focus for big pharma, with the Alexion acquisition marking AZ’s first major

  • Alexion eyes Soliris combo with $930m deal to buy Achillion Alexion eyes Soliris combo with $930m deal to buy Achillion

    Additional shares will be tied to various milestones. Alexion has added to its rare blood disorder pipeline with a $930m agreement to buy smaller biotech Achillion Pharma. ... The drug currently accounts for more than 80% of Alexion’s sales, but is

  • Bluebird and Alexion veterans launch cell and gene venture ElevateBio Bluebird and Alexion veterans launch cell and gene venture ElevateBio

    Massachusetts. The company was unveiled yesterday by its co-founders David Hallal and Vikas Sinha, previously last chief exec and chief financial officer respectively of Alexion, with ex-Bluebird Bio chief ... Hallal and Sinha left Alexion under a cloud

  • CHMP nod for Alexion, GSK drugs, revocation for Lartruvo CHMP nod for Alexion, GSK drugs, revocation for Lartruvo

    The CHMP recommended 13 medicines last Friday, including Ultomiris, Alexion’s follow-up to its rare disease blockbuster Soliris, and GSK’s single pill, two-drug HIV regimen, Dovato. ... Dova Pharma’s Doptelet (avatrombopag) for the treatment of

  • Alexion targets RNAi with $637m Dicerna deal Alexion targets RNAi with $637m Dicerna deal

    Alexion already has a follow-on complement inhibitor to be the next generation replacement for Soliris. ... With Soliris, Alexion has demonstrated the transformative impact of complement inhibition on multiple serious and debilitating diseases.

More from news
Approximately 0 fully matching, plus 17 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Alexion Pharmaceuticals adds to its board Alexion Pharmaceuticals adds to its board

    Judith Reinsdorf recently worked at Johnson Controls. Alexion Pharmaceuticals has appointed Judith Reinsdorf to its board of directors following her role as executive vice president and general counsel of Johnson Controls. ... David Brennan, chairman of

  • Alexion appoints new senior VP for EMEAC region Alexion appoints new senior VP for EMEAC region

    Camilla Harder Hartvig will lead commercial activities from Zurich, Switzerland. Alexion Pharma has appointed Camilla Harder Hartvig as its senior vice president and head of its EMEAC region. ... Alexion’s global business, and look forward to

  • Alexion Pharmaceutiacal names interim CEO and CFO Alexion Pharmaceutiacal names interim CEO and CFO

    suited to lead Alexion as we embark on our next exciting phase of growth. ... We are also delighted that Dave Anderson is joining Alexion as our new chief financial officer.

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Viseven

Viseven is a full cycle digital agency with 10 years expertise in developing content for the global pharmaceutical market delivering...

Latest intelligence

Health literacy in the time of COVID-19
In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
Rare thoughts & outcomes - navigating pathways to better outcomes in rare
...
How to pick the perfect training program for your healthcare professionals
You know your team needs training. But not all training providers and programs are created equal. Last week, we shared the benefits of working with specialist learning and development (L&D)...